160 related articles for article (PubMed ID: 20922195)
1. Cyclic antibiotic therapy for diverticular disease: a critical reappraisal.
Zullo A; Hassan C; Maconi G; Manes G; Tammaro G; De Francesco V; Annibale B; Ficano L; Buri L; Gatto G; Lorenzetti R; Campo SM; Ierardi E; Pace F; Morini S
J Gastrointestin Liver Dis; 2010 Sep; 19(3):295-302. PubMed ID: 20922195
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.
Bianchi M; Festa V; Moretti A; Ciaco A; Mangone M; Tornatore V; Dezi A; Luchetti R; De Pascalis B; Papi C; Koch M
Aliment Pharmacol Ther; 2011 Apr; 33(8):902-10. PubMed ID: 21366632
[TBL] [Abstract][Full Text] [Related]
3. [Role of rifaximin in the treatment of colonic diverticular disease].
Moretti A; Spagnolo A; Mangone M; Chiesara F; Aratari A; Papi C; Koch M
Clin Ter; 2012; 163(1):33-8. PubMed ID: 22362232
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE).
Cuomo R; Barbara G; Annibale B
Dig Liver Dis; 2017 Jun; 49(6):595-603. PubMed ID: 28215517
[TBL] [Abstract][Full Text] [Related]
5. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review.
Maconi G; Barbara G; Bosetti C; Cuomo R; Annibale B
Dis Colon Rectum; 2011 Oct; 54(10):1326-38. PubMed ID: 21904150
[TBL] [Abstract][Full Text] [Related]
6. One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study.
Lanas A; Ponce J; Bignamini A; Mearin F
Dig Liver Dis; 2013 Feb; 45(2):104-9. PubMed ID: 23092785
[TBL] [Abstract][Full Text] [Related]
7. Interaction between rifaximin and dietary fibre in patients with diverticular disease.
D'Incà R; Pomerri F; Vettorato MG; Dal Pont E; Di Leo V; Ferronato A; Medici V; Sturniolo GC
Aliment Pharmacol Ther; 2007 Apr; 25(7):771-9. PubMed ID: 17373915
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease.
Colecchia A; Vestito A; Pasqui F; Mazzella G; Roda E; Pistoia F; Brandimarte G; Festi D
World J Gastroenterol; 2007 Jan; 13(2):264-9. PubMed ID: 17226906
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
Latella G; Pimpo MT; Sottili S; Zippi M; Viscido A; Chiaramonte M; Frieri G
Int J Colorectal Dis; 2003 Jan; 18(1):55-62. PubMed ID: 12458383
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group.
Papi C; Ciaco A; Koch M; Capurso L
Ital J Gastroenterol; 1992 Oct; 24(8):452-6. PubMed ID: 1330083
[TBL] [Abstract][Full Text] [Related]
11. Management of diverticular disease: is there room for rifaximin?
Papi C; Koch M; Capurso L
Chemotherapy; 2005; 51 Suppl 1():110-4. PubMed ID: 15855755
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease.
Brandimarte G; Tursi A
Med Sci Monit; 2004 May; 10(5):PI70-3. PubMed ID: 15114281
[TBL] [Abstract][Full Text] [Related]
13. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.
Tursi A; Papa A; Danese S
Aliment Pharmacol Ther; 2015 Sep; 42(6):664-84. PubMed ID: 26202723
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.
Papi C; Ciaco A; Koch M; Capurso L
Aliment Pharmacol Ther; 1995 Feb; 9(1):33-9. PubMed ID: 7766741
[TBL] [Abstract][Full Text] [Related]
15. Non-absorbable antibiotics in the treatment of diverticular disease of the colon.
Papi C; Camarri E
Ital J Gastroenterol; 1992; 24(9 Suppl 2):19-22. PubMed ID: 1336684
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin in the management of colonic diverticular disease.
Latella G; Scarpignato C
Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):585-98. PubMed ID: 19929580
[TBL] [Abstract][Full Text] [Related]
17. Rationale and evidences for treatment of symptomatic uncomplicated diverticular disease.
Cuomo R; Cargiolli M; Andreozzi P; Zito FP; Sarnelli G
Minerva Gastroenterol Dietol; 2017 Jun; 63(2):130-142. PubMed ID: 27973463
[TBL] [Abstract][Full Text] [Related]
18. Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease.
Stallinger S; Eller N; Högenauer C
Wien Klin Wochenschr; 2014 Jan; 126(1-2):9-14. PubMed ID: 24240607
[TBL] [Abstract][Full Text] [Related]
19. Does rifaximin prevent complications of diverticular disease? A retrospective study.
Pistoia MA; Lombardi L; Rossi M; Vittorini C; Cavaliere GF; Pistoia F
Eur Rev Med Pharmacol Sci; 2004; 8(6):283-7. PubMed ID: 15745388
[TBL] [Abstract][Full Text] [Related]
20. Diverticular Disease and Rifaximin: An Evidence-Based Review.
Piccin A; Gulotta M; di Bella S; Martingano P; Crocè LS; Giuffrè M
Antibiotics (Basel); 2023 Feb; 12(3):. PubMed ID: 36978310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
